Cytokinetics, Incorporated (CYTK) Financials
CYTK Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 824.3 million | 1.2 billion |
2023-09-30 | 740.6 million | 1.2 billion |
2023-06-30 | 779.9 million | 1.1 billion |
2023-03-31 | 889.8 million | 1.1 billion |
CYTK Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -74.1 million | 19.5 million |
2023-09-30 | -96.4 million | 18.7 million |
2023-06-30 | -122.5 million | 18.7 million |
2023-03-31 | -122.7 million | 15.2 million |
CYTK Net Income
No data available :(
CYTK Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 615.2 million | - | 138.3 million |
2023-09-30 | 539.2 million | - | 139.5 million |
2023-06-30 | 565.7 million | - | 139.5 million |
2023-03-31 | 664.0 million | 64.1 million | 139.6 million |
CYTK Shares Outstanding
CYTK Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 77000 | 78.6 million | 44.1 million | - |
2023-09-30 | 220000 | 378000 | 40.1 million | - |
2023-06-30 | 717000 | 867000 | 39.7 million | - |
2023-03-31 | 402000 | 2.1 million | 49.7 million | - |
CYTK Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 1.7 million | 6.3 million |
2023-09-30 | 378000 | 82.5 million |
2023-06-30 | 867000 | 83.2 million |
2023-03-31 | 4.6 million | 79.4 million |
CYTK
Price: $63.37
52 week price:
Payout Ratio Range:
Earnings Per Share: -5.45 USD
P/E Ratio: -14.75
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 998300
Ebitda: -35.8 millionMarket Capitalization: 7.1 billion